Physician profile
Lee E Moore
NPI 1699156950
$16,981.77
in general payments reported to CMS, 2019-2025
23 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 78% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $550 · 2021: $2,759 · 2022: $10K · 2023: $797 · 2024: $1,023 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.36 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $9,161.79 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Glaukos Corporation | $3,505.00 | 2019-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl1b-Ce-Marked Kxlsystem |
| Oyster Point Pharma, INC. | $903.87 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $854.90 | 2019-2025 | Catalys System, Amo Phaco Needle, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $652.22 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $428.01 | 2022-2025 | |
| Biotissue Holdings INC. | $349.16 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $198.14 | 2020-2023 | |
| Allergan, INC. | $174.60 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $129.09 | 2025 | Acthar |
| Ocular Therapeutix, INC. | $97.72 | 2021-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $93.00 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.70 | 2020-2021 | |
| Alcon Vision LLC | $76.06 | 2019-2025 | Rocklatan, Clareon, Centurion |
| Thea Pharma INC. | $62.07 | 2024-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $47.35 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $31.55 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $26.92 | 2022 | |
| Aerie Pharmaceuticals, INC. | $24.44 | 2020 | |
| Rayner Intraocular Lenses Limited | $23.00 | 2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Ani Pharmaceuticals, INC. | $20.60 | 2023 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $18.76 | 2024 | Xdemvy |
| Amgen INC. | $14.82 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.